Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biofrontera AGLTS:0DOL 62 3-1 Month Momentum % is -11.33% as of Aug. 19, 2026. GuruFocus rates LTS:0DOL with a GF Score™ of 62/100 and a GF Value™ of €2.36. The stock has 4 warning signs investors should review. Among 1,020 Drug Manufacturers companies, Biofrontera AG ranks worse than 50.59% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-19), Biofrontera AG's 3-1 Month Momentum % is -11.33%.
The industry rank for Biofrontera AG's 3-1 Month Momentum % or its related term are showing as below:
LTS:0DOL's 3-1 Month Momentum % is ranked worse than 50.59% of 1020
companies
in the Drug Manufacturers industry
Industry Median: -4.54
vs LTS:0DOL: -11.33
Biofrontera AG (LTS:0DOL) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Biofrontera AG 3-1 Month Momentum % Related Terms
LTS:0DOL vs ZTS, UTHR, VTRS: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofrontera AG 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Biofrontera AG's 3-1 Month Momentum % falls into.
Biofrontera AG (LTS:0DOL) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofrontera AG (LTS:0DOL) has a 3-1 Month Momentum % of -11.33% as of Aug. 19, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Biofrontera AG and its competitors. According to the industry distribution chart, Biofrontera AG ranks #516 out of 1020 companies in the Drug Manufacturers industry, placing it in the top 50.6%.
Is Biofrontera AG's 3-1 Month Momentum % too high?
Biofrontera AG's current 3-1 Month Momentum % is -11.33%. Based on the distribution chart, Biofrontera AG ranks #516 out of 1020 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Biofrontera AG has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Biofrontera AG's 3-1 Month Momentum % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biofrontera AG ranks #516 out of 1020 companies for 3-1 Month Momentum %. This places Biofrontera AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Biofrontera AG and its competitors. Biofrontera AG's current 3-1 Month Momentum % is -11.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera AG stock overvalued right now?
Biofrontera AG (LTS:0DOL) has a current 3-1 Month Momentum % of -11.33%. The stock's GF Value™ is €2.36, compared to a current price of €2.49 — trading 5.5% above its estimated fair value. The current 3-1 Month Momentum % is -11.33%. Biofrontera AG's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Biofrontera AG (LTS:0DOL), the current 3-1 Month Momentum % is -11.33% as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofrontera AG (LTS:0DOL) Overvalued in 2026?
Based on GuruFocus' analysis, Biofrontera AG stock appears to be overvalued.
The current stock price of €2.49 is trading 5.5% above its estimated GF Value™ of €2.36.
Key valuation signals for LTS:0DOL:
3-1 Month Momentum %: -11.33%
GF Value™: €2.36 vs. price of €2.49 (5.5% above fair value)
No single metric tells the full story. See the LTS:0DOL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
62GF Score
Get the complete analysis for LTS:0DOL
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DOL has been successfully added to your 
